Burkitt Lymphoma/Leukaemia in Children & Young Adolescents
Aims Burkitt Lymphoma (BL) accounts for approximately 40% of childhood non-Hodgkin Lymphoma (NHL) in the developed world. Survival rates have improved dramatically in recent years, a success attributed to better use of poly-chemotherapy and targeted immunotherapy. Nevertheless, relapse is unpredicta...
Gespeichert in:
| Veröffentlicht in: | Irish medical journal 2020-01, Vol.113 (1), p.6-6 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6 |
|---|---|
| container_issue | 1 |
| container_start_page | 6 |
| container_title | Irish medical journal |
| container_volume | 113 |
| creator | O'Rourke, E Malone, A O'Marcaigh, A Storey, L Betts, D McDermott, M Smith, O P |
| description | Aims Burkitt Lymphoma (BL) accounts for approximately 40% of childhood non-Hodgkin Lymphoma (NHL) in the developed world. Survival rates have improved dramatically in recent years, a success attributed to better use of poly-chemotherapy and targeted immunotherapy. Nevertheless, relapse is unpredictable and carries a dismal prognosis. We report on event-free survival (EFS) and overall survival (OS) rates in the Republic of Ireland (ROI) during 2000-2017, and evaluate novel predictors of outcome. Methods Data was collected by retrospective review of patient medical records. Results Thirty-three patients were identified (twenty-five [76%] males, eight [24%] females), fourteen [42%] having stage III disease at presentation. Six [18%] had stage IV disease. Five [15%] had refractory disease; one salvaged with allogeneic stem cell transplantation. Of the four [12%] who died; two [50%] had weights >99th centile, one [25%] >90th centile. One died during induction from refractory lactic acidosis, one from early relapse. Discussion EFS and OS was 85% and 89% respectively; in keeping with the best international standards. Obesity appears to be a poor predictor of outcome in our cohort. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2391977774</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2391977774</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-62fe6114245529d7cd0b2374c2b1765e6ce9f36376b440d9447d9914d3a7625e3</originalsourceid><addsrcrecordid>eNo1j7FOwzAURT2AaCn8AvKEWCLsZ8eu2UpFASkSCwxMkRO_UNM4CXE89O-JRLnLXY6uzj0jSyYEZIIzWJDLGL8ZEyA0XJCFADDrXK2X5OExjQc_TbQ4hmHfB3tfYDpYDN5S39Ht3rduxI7e0s8-dV904_oWY43dFK_IeWPbiNenXpGP3dP79iUr3p5ft5siGzioKVPQoOJcgsxzME7XjlWzhqyh4lrlqGo0jVBCq0pK5oyU2hnDpRNWK8hRrMjd3-4w9j8J41QGPxu0re2wT7EEYbjRc-SM3pzQVAV05TD6YMdj-f9X_AIGbE4w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2391977774</pqid></control><display><type>article</type><title>Burkitt Lymphoma/Leukaemia in Children & Young Adolescents</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>O'Rourke, E ; Malone, A ; O'Marcaigh, A ; Storey, L ; Betts, D ; McDermott, M ; Smith, O P</creator><creatorcontrib>O'Rourke, E ; Malone, A ; O'Marcaigh, A ; Storey, L ; Betts, D ; McDermott, M ; Smith, O P</creatorcontrib><description>Aims Burkitt Lymphoma (BL) accounts for approximately 40% of childhood non-Hodgkin Lymphoma (NHL) in the developed world. Survival rates have improved dramatically in recent years, a success attributed to better use of poly-chemotherapy and targeted immunotherapy. Nevertheless, relapse is unpredictable and carries a dismal prognosis. We report on event-free survival (EFS) and overall survival (OS) rates in the Republic of Ireland (ROI) during 2000-2017, and evaluate novel predictors of outcome. Methods Data was collected by retrospective review of patient medical records. Results Thirty-three patients were identified (twenty-five [76%] males, eight [24%] females), fourteen [42%] having stage III disease at presentation. Six [18%] had stage IV disease. Five [15%] had refractory disease; one salvaged with allogeneic stem cell transplantation. Of the four [12%] who died; two [50%] had weights >99th centile, one [25%] >90th centile. One died during induction from refractory lactic acidosis, one from early relapse. Discussion EFS and OS was 85% and 89% respectively; in keeping with the best international standards. Obesity appears to be a poor predictor of outcome in our cohort.</description><identifier>ISSN: 0332-3102</identifier><identifier>PMID: 32298568</identifier><language>eng</language><publisher>Ireland</publisher><ispartof>Irish medical journal, 2020-01, Vol.113 (1), p.6-6</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32298568$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>O'Rourke, E</creatorcontrib><creatorcontrib>Malone, A</creatorcontrib><creatorcontrib>O'Marcaigh, A</creatorcontrib><creatorcontrib>Storey, L</creatorcontrib><creatorcontrib>Betts, D</creatorcontrib><creatorcontrib>McDermott, M</creatorcontrib><creatorcontrib>Smith, O P</creatorcontrib><title>Burkitt Lymphoma/Leukaemia in Children & Young Adolescents</title><title>Irish medical journal</title><addtitle>Ir Med J</addtitle><description>Aims Burkitt Lymphoma (BL) accounts for approximately 40% of childhood non-Hodgkin Lymphoma (NHL) in the developed world. Survival rates have improved dramatically in recent years, a success attributed to better use of poly-chemotherapy and targeted immunotherapy. Nevertheless, relapse is unpredictable and carries a dismal prognosis. We report on event-free survival (EFS) and overall survival (OS) rates in the Republic of Ireland (ROI) during 2000-2017, and evaluate novel predictors of outcome. Methods Data was collected by retrospective review of patient medical records. Results Thirty-three patients were identified (twenty-five [76%] males, eight [24%] females), fourteen [42%] having stage III disease at presentation. Six [18%] had stage IV disease. Five [15%] had refractory disease; one salvaged with allogeneic stem cell transplantation. Of the four [12%] who died; two [50%] had weights >99th centile, one [25%] >90th centile. One died during induction from refractory lactic acidosis, one from early relapse. Discussion EFS and OS was 85% and 89% respectively; in keeping with the best international standards. Obesity appears to be a poor predictor of outcome in our cohort.</description><issn>0332-3102</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNo1j7FOwzAURT2AaCn8AvKEWCLsZ8eu2UpFASkSCwxMkRO_UNM4CXE89O-JRLnLXY6uzj0jSyYEZIIzWJDLGL8ZEyA0XJCFADDrXK2X5OExjQc_TbQ4hmHfB3tfYDpYDN5S39Ht3rduxI7e0s8-dV904_oWY43dFK_IeWPbiNenXpGP3dP79iUr3p5ft5siGzioKVPQoOJcgsxzME7XjlWzhqyh4lrlqGo0jVBCq0pK5oyU2hnDpRNWK8hRrMjd3-4w9j8J41QGPxu0re2wT7EEYbjRc-SM3pzQVAV05TD6YMdj-f9X_AIGbE4w</recordid><startdate>20200116</startdate><enddate>20200116</enddate><creator>O'Rourke, E</creator><creator>Malone, A</creator><creator>O'Marcaigh, A</creator><creator>Storey, L</creator><creator>Betts, D</creator><creator>McDermott, M</creator><creator>Smith, O P</creator><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20200116</creationdate><title>Burkitt Lymphoma/Leukaemia in Children & Young Adolescents</title><author>O'Rourke, E ; Malone, A ; O'Marcaigh, A ; Storey, L ; Betts, D ; McDermott, M ; Smith, O P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-62fe6114245529d7cd0b2374c2b1765e6ce9f36376b440d9447d9914d3a7625e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>O'Rourke, E</creatorcontrib><creatorcontrib>Malone, A</creatorcontrib><creatorcontrib>O'Marcaigh, A</creatorcontrib><creatorcontrib>Storey, L</creatorcontrib><creatorcontrib>Betts, D</creatorcontrib><creatorcontrib>McDermott, M</creatorcontrib><creatorcontrib>Smith, O P</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Irish medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>O'Rourke, E</au><au>Malone, A</au><au>O'Marcaigh, A</au><au>Storey, L</au><au>Betts, D</au><au>McDermott, M</au><au>Smith, O P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Burkitt Lymphoma/Leukaemia in Children & Young Adolescents</atitle><jtitle>Irish medical journal</jtitle><addtitle>Ir Med J</addtitle><date>2020-01-16</date><risdate>2020</risdate><volume>113</volume><issue>1</issue><spage>6</spage><epage>6</epage><pages>6-6</pages><issn>0332-3102</issn><abstract>Aims Burkitt Lymphoma (BL) accounts for approximately 40% of childhood non-Hodgkin Lymphoma (NHL) in the developed world. Survival rates have improved dramatically in recent years, a success attributed to better use of poly-chemotherapy and targeted immunotherapy. Nevertheless, relapse is unpredictable and carries a dismal prognosis. We report on event-free survival (EFS) and overall survival (OS) rates in the Republic of Ireland (ROI) during 2000-2017, and evaluate novel predictors of outcome. Methods Data was collected by retrospective review of patient medical records. Results Thirty-three patients were identified (twenty-five [76%] males, eight [24%] females), fourteen [42%] having stage III disease at presentation. Six [18%] had stage IV disease. Five [15%] had refractory disease; one salvaged with allogeneic stem cell transplantation. Of the four [12%] who died; two [50%] had weights >99th centile, one [25%] >90th centile. One died during induction from refractory lactic acidosis, one from early relapse. Discussion EFS and OS was 85% and 89% respectively; in keeping with the best international standards. Obesity appears to be a poor predictor of outcome in our cohort.</abstract><cop>Ireland</cop><pmid>32298568</pmid><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0332-3102 |
| ispartof | Irish medical journal, 2020-01, Vol.113 (1), p.6-6 |
| issn | 0332-3102 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2391977774 |
| source | EZB-FREE-00999 freely available EZB journals |
| title | Burkitt Lymphoma/Leukaemia in Children & Young Adolescents |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T11%3A17%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Burkitt%20Lymphoma/Leukaemia%20in%20Children%20&%20Young%20Adolescents&rft.jtitle=Irish%20medical%20journal&rft.au=O'Rourke,%20E&rft.date=2020-01-16&rft.volume=113&rft.issue=1&rft.spage=6&rft.epage=6&rft.pages=6-6&rft.issn=0332-3102&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E2391977774%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2391977774&rft_id=info:pmid/32298568&rfr_iscdi=true |